Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer

Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical

Patent Protects Rights to ADXS-HPV to 2028

PRINCETON, N.J., March 18, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc.
(Nasdaq:ADXS), a biotechnology company developing the next generation of
cancer immunotherapies, today announced that it has been issued a significant
patent from the Japan Patent Office, entitled, "Compositions and Methods for
Enhancing Immunogenicity of Antigens". The claims of the patent (patent number
5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical
cancer with a term that extends to 2028.

"Receiving this patent in Japan for our proprietary immunotherapy product
candidate, ADXS-HPV, to be used in treating patients with late-stage cervical
cancer is an important milestone," commented Daniel J. O'Connor, Chief
Executive Officer of Advaxis. "This expands our patent portfolio which already
has over 40 patents issued and over 40 patents pending worldwide. With
licensing agreements established in Asia, with Global BioPharma, and India,
with Biocon Ltd., Advaxis is positioned for global development and
commercialization of our immunotherapies to treat cervical cancer. Expanding
the protection of our intellectual property is a major component of this

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next
generation of cancer immunotherapies. Advaxis's immunotherapies are based on a
novel platform technology using live, attenuated bacteria to stimulate the
immune system to selectively target cancer cells while reducing tumor

ADXS-HPV, Advaxis's lead immunotherapy for the treatment of HPV-associated
cancers, has demonstrated improved survival and objective tumor responses in a
Phase 2 trial in 110 patients with recurrent cervical cancer. Advaxis is now
planning the registrational program for ADXS-HPV. ADXS-HPV is also being
evaluated in other HPV-associated cancers including a Phase 2 in advanced
cervical cancer, a Phase 1/2 in head and neck cancer, and a Phase 1/2 in anal
cancer. ADXS-HPV has orphan drug status for both anal and head and neck
cancers. As part of its global commercialization strategy to enter into
regional licensing deals with other market dominant biopharmaceutical
companies in territories where there is a high prevalence of HPV-associated
cancers, Advaxis has granted exclusive licenses for the development and
commercialization of ADXS-HPV in Asia and India.

ADXS-cHER2 is an immunotherapy for the treatment of HER2-overexpressing
cancers (such as breast, gastric, esophageal, and other cancers in humans and
for osteosarcoma in canines). Advaxis' lead animal-health immunotherapy,
ADXS-cHER2, has demonstrated encouraging survival data in a Phase 1 trial in
canine osteosarcoma. These data provide the rationale to advance this same
immunotherapy into a Phase 1 clinical trial in patients with
HER2-overexpressing cancers such as breast, gastric, esophageal, and others.
The Company is preparing an IND submission for ADXS-cHER2 in the treatment of
HER2 overexpressing cancers in 2014.

Advaxis has created more than 20 distinct immunotherapies based on its
platform, either directly or through strategic collaborations with recognized
cancer centers of excellence. We have clinical research collaborations with
the University of Pennsylvania, Brown University, the Georgia Regents
University Cancer Center, the Icahn School of Medicine at Mount Sinai, and

For more information please visit or connect with us on


Forward-Looking Statements

This news release contains forward-looking statements, including, but not
limited to: statements regarding Advaxis's ability to develop the next
generation of cancer immunotherapies; the safety and efficacy of Advaxis's
proprietary immunotherapy, ADXS-HPV; whether Advaxis immunotherapies can
redirect the powerful immune response all human beings have to the bacterium
to cancers. These forward-looking statements are subject to a number of risks,
including the risk factors set forth from time to time in Advaxis's SEC
filings, including but not limited to its report on Form 10-K for the fiscal
year ended October 31, 2013, which is available at Advaxis
undertakes no obligation to publicly release the result of any revision to
these forward-looking statements, which may be made to reflect the events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, except as required by law. You are cautioned not to
place undue reliance on any forward-looking statements.

CONTACT: Advaxis Contact:
         Lisa Caperelli
         Senior Director of Investor Relations and Corporate Communications
         Advaxis, Inc.
         Media Contact:
         Tiberend Strategic Advisors, Inc.
         Andrew Mielach

Advaxis logo
Press spacebar to pause and continue. Press esc to stop.